Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer

Molecular Cancer Therapeutics

Volumn 3, Issue 8, 2004, Pages 921-932

  Afar, Daniel E H ^a   Bhaskar, Vinay ^a   Ibsen, Eric ^a   Breinberg, Danna ^a   Henshall, Susan M ^b   Kench, James G ^b,c   Drobnjak, Marija ^d   Powers, Rick ^a   Wong, Melanie ^a   Evangelista, Ferdinand ^a   O'Hara, Chris ^a   Powers, David ^a   DuBridge, Robert B ^a   Caras, Ingrid ^a   Winter, Ruth ^e   Anderson, Terri ^a   Solvason, Nanette ^e   Stricker, Phillip D ^b   Cordon Cardo, Carlos ^d   Scher, Howard I ^d   Grygiel, John J ^b   Sutherland, Robert L ^b   Murray, Richard ^a   Ramaskrishnan, Vanitha ^a   Law, Debbie A ^a   more..

^a PROTEIN DESIGN LABS INC   (United States)

^b ST VINCENT S HOSPITAL   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e Bioinformatics Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; AURISTATIN E MONOCLONAL ANTIBODY PR1 CONJUGATE; CATHEPSIN B; CITRULLINE; EPIDERMAL GROWTH FACTOR; FOLLISTATIN; PLASMA PROTEIN; TOMOREGULIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; CANCER INHIBITION; COMBINED IMMUNODEFICIENCY; CONTROLLED STUDY; CROSS REACTION; DISEASE SEVERITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG MEGADOSE; GENE OVEREXPRESSION; HORMONE RESISTANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

EID: 4444297534     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.921.3.8     Document Type: Article

References (41)

1. Smaletz O, Scher HI. Outcome predictions for patients with metastatic prostate cancer. Semin Urol Oncol 2002;20:155-63.
2. Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br J Cancer 2003;89:968-70.
3. Meluch AA, Greco FA, Morrissey LH, et al. Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial. Cancer 2003;98:2192-8.
4. Petrylak DP. Chemotherapy for androgen-independent prostate cancer. Semin Urol Oncol 2002;20:31-5.
5. Autorino R, Di Lorenzo G, Damiano R, De Placido S, D'Armiento M. Role of chemotherapy in hormone-refractory prostate cancer. Old issues, recent advances and new perspectives. Urol Int 2003;70:1-14.
6. Braslawsky GR, Edson MA, Pearce W, Kaneko T, Greenfield RS. Antitumor activity of Adriamycin (hydrazone-linked) immunoconjugates compared with free Adriamycin and specificity of tumor cell killing. Cancer Res 1990;50:6608-14.
7. Bernstein ID. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 2000;14:474-5.
8. Bhaskar V, Law DA, Ibsen E, et al. E-selectin up-regulation allows for targeted drug delivery in prostate cancer. Cancer Res 2003;63: 6387-94.
9. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84.
10. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-65.
11. Liu C, Tadayoni BM, Bourret LA, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci USA 1996;93:8618-23.
12. Ross S, Spencer SD, Holcomb I, et al. Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res 2002;62:2546-53.
13. Tolcher AW, Ochoa L, Hammond LA, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003;21:211-22.
14. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003;30:667-76.
15. Bubendorf L, Kolmer M, Kononen J, et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 1999;91:1758-64.
16. Luo J, Duggan DJ, Chen Y, et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res 2001;61:4683-8.
17. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8.
18. Luo J, Isaacs WB, Trent JM, Duggan DJ. Looking beyond morphology: cancer gene expression profiling using DNA microarrays. Cancer Invest 2003;21:937-49.
19. Henshall SM, Afar DE, Rasiah KK, et al. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene 2003;22:6005-12.
20. Horie M, Mitsumoto Y, Kyushiki H, et al. Identification and characterization of TMEFF2, a novel survival factor for hippocampal and mesencephalic neurons. Genomics 2000;67:146-52.
21. Uchida T, Wada K, Akamatsu T, et al. A novel epidermal growth factor-like molecule containing two follistatin modules stimulates tyrosine phosphorylation of erbB-4 in MKN28 gastric cancer cells. Biochem Biophys Res Commun 1999;266:593-602.
22. Liang G, Robertson KD, Talmadge C, Sumegi J, Jones PA. The gene for a novel transmembrane protein containing epidermal growth factor and follistatin domains is frequently hypermethylated in human tumor cells. Cancer Res 2000;60:4907-12.
23. Glynne-Jones E, Harper ME, Seery LT, et al. TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independence. Int J Cancer 2001;94:178-84.
24. Henshall SM, Afar DE, Hiller J, et al. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003;63:4196-203.
25. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. 5th ed. Washington (DC): U.S. Department of Health and Human Services, NIH; 1991.
26. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989;86: 10029-33.
27. Wang X, Stollar BD. Immunoglobulin VH gene expression in human aging. Clin Immunol 1999;93:132-42.
28. van Den Brink EN, Turenhout EA, Davies J, et al. Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. Blood 2000;95:558-63.
29. Stemmer WP, Crameri A, Ha KD, Brennan TM, Heyneker HL. Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Gene 1995;164:49-53.
30. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-7.
31. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-18.
32. Pretlow TG, Wolman SR, Micale MA, et al. Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 1993;85:394-8.
33. Dixon SC, Knopf KB, Figg WD. The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol Rev 2001;53:73-91.
34. Young J, Biden KG, Simms LA, et al. HPP1: a transmembrane protein-encoding gene commonly methylated in colorectal polyps and cancers. Proc Natl Acad Sci USA 2001;98:265-70.
35. Gary S, Sawyers CL, Agus DB, Said JW, Koeffler HP. TMEFF2 is an androgen-regulated gene exhibiting anti proliferative effects in prostate cancer cells. Oncogene 2002;21:4739-46.
36. Mohler JL, Morris TL, Ford OH III, Alvey RF, Sakamoto C, Gregory CW. Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer. Prostate 2002;51: 247-55.
37. Co MS, Queen C. Humanized antibodies for therapy. Nature 1991; 351:501-2.
38. Hooijberg E, Sein JJ, van den Berk PC, et al. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. Cancer Res 1995;55:2627-34.
39. Trail PA, Willner D, Knipe J, et al. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. Cancer Res 1997;57:100-5.
40. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH. Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate 2004;58:145-55.
41. Kanemoto N, Horie M, Omori K, et al. Expression of TMEFF1 mRNA in the mouse central nervous system: precise examination and comparative studies of TMEFF1 and TMEFF2. Brain Res Mol Brain Res 2001;86: 48-55.